US 7,428,707 · Application 10/698,332 · Granted Sep 23, 2008
US 7,428,707
Customizable web site access system and method therefore
Estimated expiration
April 27, 2024
Expired 864 days ago
Earliest effective filing
Oct 22, 2001
+ 20 years
Oct 22, 2021
PTA +918d
Apr 27, 2024
No TD
—
Final
Apr 27, 2024
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- October 31, 2003
- Earliest effective filing
- October 22, 2001
- Issue date
- September 23, 2008
- PTA
- +918 days
- Base expiry (before PTA)
- October 22, 2021
October 22, 2001 + 20 years = October 22, 2021 + 918 PTA days = April 27, 2024
- Continuation-in-part of application 10/014,929, filed Oct 22, 2001, issued as US 7,171,629
- PRO60/422,731 — Provisional — not used for base term
- PRO60/242,340 — Provisional — not used for base term
- PRO60/286,189 — Provisional — not used for base term
- PRO60/242,340 — Provisional — not used for base term
- PRO60/286,189 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 10/698,332 · US 7,428,707
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 7,428,707: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US7428707Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.